Clinical efficacy of dacogen in myelodysplastic syndrome

Abstract

Clinical efficiency of Dacogen (inhibitor of DNA hypermethylation) in 16 patients with MDS is presented. Bone marrow cytogenetic studies were performed in 6 patients; the detected chromosome aberrations included 5q deletion in 1 patient, X monosomy in 2 and multiple clonal rearrangements in 1. Results of this study indicated that after 4 courses of Dacogen (15mg/m2 i.v. 3 times daily for 3 days each course) significant clinical and hematological effects is received (according to standard criteria [1]): a complete response was in 3 patients; no partial response was registered; stabilization and bone marrow remission were achieved in 1 and 4 patients respectively. Response duration was 3.5 months. Drug myelotoxicity which would influence on intercourse interval and cause dose reduction during treatment was not revealed.

Keywords

• myelodysplastic syndrome
• adult patients
• dacogen
• efficiency
• toxicity